Get the Stockscreener App
2.57
2.28%
-0.06
Geron Corp stock is traded at $2.57, with a volume of 8.90M.
It is down -2.28% in the last 24 hours and down -13.18% over the past month.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
See More
Previous Close:
$2.63
Open:
$2.635
24h Volume:
8.90M
Relative Volume:
0.84
Market Cap:
$1.55B
Revenue:
$29.48M
Net Income/Loss:
$-201.19M
P/E Ratio:
-8.0313
EPS:
-0.32
Net Cash Flow:
$-216.50M
1W Performance:
+0.39%
1M Performance:
-13.18%
6M Performance:
-43.39%
1Y Performance:
+33.16%
1-Day Range:
$2.555
$2.66
1-Week Range:
$2.49
$2.70
52-Week Range:
$1.64
$5.34
Geron Corp Stock (GERN) Company Profile
Name
Geron Corp
Sector
Industry
Phone
(650) 473-7700
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
2.57 | 1.55B | 29.48M | -201.19M | -216.50M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Initiated | Leerink Partners | Outperform |
| Apr-30-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-29-24 | Initiated | TD Cowen | Buy |
| Mar-15-24 | Reiterated | Needham | Buy |
| Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-28-23 | Initiated | Goldman | Neutral |
| Oct-28-22 | Initiated | Wedbush | Outperform |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Nov-02-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Resumed | B. Riley Securities | Buy |
| Aug-03-20 | Initiated | Stifel | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Sep-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-09-19 | Upgrade | Needham | Hold → Buy |
| Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
| Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-13-16 | Reiterated | FBR & Co. | Outperform |
| Sep-13-16 | Reiterated | FBR Capital | Outperform |
| Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
| Dec-10-13 | Reiterated | MLV & Co | Buy |
| Dec-10-13 | Upgrade | Needham | Hold → Buy |
| Nov-08-13 | Reiterated | MLV & Co | Buy |
| Oct-16-13 | Initiated | MLV & Co | Buy |
| Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
| Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp Stock (GERN) Latest News
GERNGeron Corp Latest Stock News & Market Updates - StockTitan
Commercial-Stage Biotech Geron Lines Up Triple Conference ShowcaseKey Dates Inside - StockTitan
Geron Co. (NASDAQ:GERN) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Geron (GERN) to Release Quarterly Earnings on Wednesday - MarketBeat
What is B. Riley's Estimate for Geron FY2027 Earnings? - MarketBeat
B. Riley Has Lowered Expectations for Geron (NASDAQ:GERN) Stock Price - MarketBeat
Inside Geron's Latest Executive Compensation Package: Key Details on $2.63 Stock Options - StockTitan
4 Analysts Assess Geron: What You Need To Know - Benzinga
B.Riley cuts Geron stock price target to $3.50, maintains Buy - Investing.com
Analysts Set Geron Co. (NASDAQ:GERN) Price Target at $7.25 - MarketBeat
Geron (NASDAQ:GERN) Shares Down 4.6%Here's Why - MarketBeat
Geron (NASDAQ:GERN) Trading Down 4.6%Here's Why - MarketBeat
abrdn plc Raises Stake in Geron Co. (NASDAQ:GERN) - MarketBeat
Is Geron Corp. (GERN) the Best Nasdaq Stock Under $5 to Buy? - Insider Monkey
Interesting GERN Put And Call Options For March 21st - Nasdaq
Chicago Partners Investment Group LLC Sells 7,756 Shares of Geron Co. (NASDAQ:GERN) - ETF Daily News
Geron Corporation: Lackluster Share Price Performance Despite Reasonable Drug Launch - Seeking Alpha
Q4 Earnings Preview: Geron Sets Critical Financial Results DateKey Details Inside - StockTitan
Nvest Financial LLC Purchases Shares of 195,741 Geron Co. (NASDAQ:GERN) - MarketBeat
Geron Corp. (NASDAQ: GERN) Faces Decline: What’s Behind the 3.92% Drop? – Market - HPBL
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Geron Corp Stock (GERN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GRETHLEIN ANDREW J | EVP, Chief Operating Officer |
Jul 08 '24 |
Sale |
4.56 |
674,348 |
3,073,004 |
0 |
| Feller Faye | EVP, Chief Medical Officer |
Jun 10 '24 |
Option Exercise |
1.19 |
287,900 |
341,693 |
155,400 |
| Feller Faye | EVP, Chief Medical Officer |
Jun 10 '24 |
Sale |
4.63 |
287,900 |
1,334,129 |
0 |
| Kapur Anil | EVP, Corp Strategy & CCO |
Jun 10 '24 |
Option Exercise |
1.06 |
421,875 |
447,188 |
421,875 |
| Kapur Anil | EVP, Corp Strategy & CCO |
Jun 10 '24 |
Sale |
4.64 |
421,875 |
1,959,609 |
0 |
| SCARLETT JOHN A | Chairman, President and CEO |
Jun 04 '24 |
Option Exercise |
2.54 |
600,000 |
1,524,000 |
600,000 |
| SCARLETT JOHN A | Chairman, President and CEO |
Jun 04 '24 |
Sale |
4.00 |
600,000 |
2,400,000 |
600,000 |
| LAWLIS V BRYAN | Director |
May 15 '24 |
Option Exercise |
1.94 |
35,000 |
67,900 |
35,000 |
| LAWLIS V BRYAN | Director |
May 15 '24 |
Sale |
3.75 |
35,000 |
131,250 |
0 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):